Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gerald Greer

Clinical Cardiac Electrophysiology Little Rock, AR Medical Doctor

NPI 1811943400 CMS profile 309617

9501 Lile Dr, Ste 600, Little Rock, AR 72205

Open in the dashboard

General payments

$41,352

412 records reported · program years 2019–2025

Research payments

$373

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$472,943 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Gerald Greer of Little Rock, AR is reported in the CMS Open Payments database as having received $41,352 across 412 general payments and $373 in research payments paid to them. Separately, studies naming them as principal investigator received $472,943 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 71st percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,385 30
2024 General $1,326 24
2023 General $3,026 25
2022 General $921 62
2021 General $1,298 104
2020 General $7,023 52
2019 General $25,372 115
2019 Research $373 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gerald Greer
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Gerald Greer were reported at $2,385. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Gerald Greer Clinical Cardiac Electrophysiology median Middle half National median
2019 $25,372 $2,361 $585–$8,260 $163
2020 $7,023 $993 $247–$4,351 $114
2021 $1,298 $1,185 $326–$4,739 $132
2022 $921 $2,073 $554–$6,789 $149
2023 $3,026 $2,568 $759–$8,159 $160
2024 $1,326 $2,557 $703–$7,403 $164
2025 $2,385 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lundbeck LLC $29,890 38 payments
  2. Abbott Laboratories $4,839 19 payments
  3. Amgen Inc. $1,213 34 payments
  4. Novartis Pharmaceuticals Corporation $1,009 87 payments
  5. CSL Behring $972 5 payments
  6. Janssen Pharmaceuticals, Inc $738 58 payments
  7. E.R. Squibb & Sons, L.L.C. $537 44 payments
  8. Pfizer Inc. $370 30 payments
  9. Medtronic Vascular, Inc. $192 2 payments
  10. AstraZeneca Pharmaceuticals LP $185 13 payments
  11. Other $1,406 82 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $26,450 10 payments
  2. Travel and Lodging $8,477 31 payments
  3. Food and Beverage $6,375 369 payments
  4. Education $51 2 payments
Products named General payments · program years 2019–2025
  1. NORTHERA $29,890 38 payments
  2. AVEIR Cardiac Rhythm Management $2,730 6 payments
  3. AVEIR Structural Heart $2,064 11 payments
  4. XARELTO $738 58 payments
  5. ENTRESTO $732 67 payments
  6. Repatha $311 24 payments
  7. ELIQUIS Cardiovascular $290 29 payments
  8. ELIQUIS Cardiovascular;Metabolic Disease $268 23 payments
  9. CAMZYOS $248 15 payments
  10. VYNDAQEL $237 20 payments
  11. Other $2,446 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Lundbeck LLC $373 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

6,173

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$1,208,905

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

27.8%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 627 $456,989
Vyndamax Tafamidis Brand 13 $293,024
Entresto Sacubitril/Valsartan Brand 203 $156,527
Xarelto Rivaroxaban Brand 100 $76,520
Droxidopa Generic 54 $54,981
Midodrine Hcl Generic 501 $38,816
Multaq Dronedarone Hcl Brand 37 $29,524
Repatha Sureclick Evolocumab Brand 24 $22,401
Praluent Pen Alirocumab Brand 23 $10,789
Sotalol Sotalol Hcl Brand 373 $8,306

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$118,894

Medicare's payments for the services billed

Medicare patients

1,059

Average age 75

Services billed

3,718

564 women, 495 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Atrial fibrillation 47%
Ischemic heart disease 45%
Heart failure 34%
Diabetes 31%
Chronic kidney disease 29%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $112
$112 — —
VYNDAQEL
  • PFIZER INC. $32
$32 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $22
$22 203 —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $21
$21 37 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $17
$17 627 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

414 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record